
Overview
AngioDynamics fiscal Q4 net sales rose 12.7%, beating analyst expectations, per LSEG data
Adjusted EPS for fiscal Q4 beat analyst estimates, per LSEG data
Co generated $16.2 mln free cash flow in Q4 due to strong growth
Outlook
AngioDynamics sees FY2026 net sales $305 - $310 mln
Company expects Med Tech net sales growth of 12% - 15%
AngioDynamics forecasts flat Med Device net sales growth
Company anticipates FY2026 gross margin 53.5% - 55.5%
Result Drivers
MED TECH GROWTH - AngioDynamics reported a 22% increase in Med Tech net sales, driven by innovative platform technologies, per CEO Jim Clemmer
OPERATIONAL EFFICIENCY - Positive adjusted EBITDA and $16.2 million free cash flow attributed to operational efficiency efforts
TARIFF HEADWINDS - Tariffs impacted gross margin by 204 basis points, but strategies are in place to mitigate future impacts
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Beat | $80.20 mln | $74.30 mln (3 Analysts) |
Q4 Adjusted EPS | Beat | -$0.03 | -$0.12 (3 Analysts) |
Q4 Adjusted Net Income | Beat | -$1 mln | -$4.97 mln (3 Analysts) |
Q4 Net Income |
| -$6.10 mln |
|
Q4 Adjusted EBITDA |
| $3.40 mln |
|
Q4 Gross Margin |
| 52.7% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AngioDynamics Inc is $16.00, about 39.8% above its July 14 closing price of $9.63
Press Release: ID:nBw8z4ZD8a